RAPP
USDRapport Therapeutics Inc. Common Stock
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$26.440
उच्च
$26.440
कम
$24.600
मात्रा
0.24M
कंपनी के मौलिक सिद्धांत
बाजार पूंजीकरण
1.2B
उद्योग
जैव प्रौद्योगिकी
देश
United States
ट्रेडिंग आँकड़े
औसत मात्रा
0.80M
एक्सचेंज
NGM
मुद्रा
USD
52-सप्ताह रेंज
संबंधित समाचार
Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
Truist Securities Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $44
Truist Securities analyst Joon Lee initiates coverage on Rapport Therapeutics with a Buy rating and announces Price Target of $44.
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
Rapport Announces Pricing of Public Offering of Common Stock
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
Rapport Announces Proposed Public Offering of Common Stock
BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $34
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics with a Buy and raises the price target from $31 to $34.
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for
संबंधित स्टॉक
GHY
PGIM Global High Yield Fund Inc.
TME
Tencent Music Entertainment Group American Depositary Shares each representing two Ordinary Shares
CHSCL
CHS Inc Cumulative Redeemable Preferred Stock Series 4
BKHAR
Black Hawk Acquisition Corporation Rights
HUBG
Hub Group Inc.
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।